Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 27 citing articles:

mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications
Yu‐Shiuan Wang, Monika Kumari, Guanhong Chen, et al.
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 65
T cell immune memory after covid-19 and vaccination
Lulu Wang, Alexander R. Nicols, Lance Turtle, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000468-e000468
Open Access | Times Cited: 25
Broad-spectrum pan-genus and pan-family virus vaccines
Chee Wah Tan, Sophie Valkenburg, Leo L. M. Poon, et al.
Cell Host & Microbe (2023) Vol. 31, Iss. 6, pp. 902-916
Open Access | Times Cited: 22
Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
Suad Hannawi, Linda Saf Eldin, Alaa Abuquta, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis
Alberto San Francisco Ramos, Carolina Liu-Sanchez, Tatiana Bovill Rose, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 266-282
Open Access | Times Cited: 6
Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
Fengcai Zhu, Ting Huang, Pengfei Jin, et al.
Vaccines (2025) Vol. 13, Iss. 1, pp. 43-43
Open Access
COVID-19 vaccines: A comprehensive review of safety and efficacy
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants
Guiqiang Wang, Kexin Zhao, Xiuli Zhao, et al.
Expert Review of Vaccines (2025)
Open Access
Developmental and reproductive toxicity (DART) study of a novel SARS-CoV-2 tetravalent recombinant protein vaccine (SCTV01E) in rats
Xiaoli Zhang, Jilei Jia, Gaojian Chen, et al.
Reproductive Toxicology (2025), pp. 108878-108878
Open Access
Immunogenicity and Safety of Bivalent Recombinant Protein COVID-19 Vaccine ZF2202: A Randomized, Open-label, Positive-controlled Trial
Huaiyu Yang, Ping Wang, Qiang Wu, et al.
Heliyon (2025), pp. e43100-e43100
Open Access
Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial
Suad Hannawi, Lixin Yan, Linda Saf Eldin, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102195-102195
Open Access | Times Cited: 15
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
Gustavo H. Dayan, Nadine Rouphael, Stephen R. Walsh, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 11, pp. 975-990
Open Access | Times Cited: 12
Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population
Loredana Frasca, Giuseppe Ocone, Raffaella Palazzo
Pathogens (2023) Vol. 12, Iss. 2, pp. 233-233
Open Access | Times Cited: 10
Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial
Jihai Tang, Qinghua Xu, C. Zhu, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 175-175
Open Access | Times Cited: 3
Immunogenicity of Bivalent Omicron BA.4/5–Adapted Vaccine in Hemodialysis Patients
Moritz Anft, Sarah Skrzypczyk, Michael Frahnert, et al.
Kidney International Reports (2023) Vol. 8, Iss. 4, pp. 939-941
Open Access | Times Cited: 9
Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern
Tyler M. Renner, Bassel Akache, Matthew Stuible, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Rational prediction of immunogenicity clustering through cross‐reactivity analysis of thirteen SARS‐CoV‐2 variants
Ziteng Liang, Jincheng Tong, Ziqi Sun, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 1
Closed Access | Times Cited: 2
Global Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread
Himanshu Ajmera, Sudarshan Singh Lakhawat, Naveen Malik, et al.
Current Protein and Peptide Science (2024) Vol. 25, Iss. 4, pp. 307-325
Closed Access | Times Cited: 2
Novel Multi-Antigen Orf-Virus-Derived Vaccine Elicits Protective Anti-SARS-CoV-2 Response in Monovalent and Bivalent Formats
Dominique J. Burri, Louis Renz, Melanie Mueller, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 490-490
Open Access | Times Cited: 2
A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations
Qian Gui, Cuige Gao, Miaomiao Zhang, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 579-579
Open Access | Times Cited: 2
Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial
Ruizhi Zhang, Junshi Zhao, Xiaoping Zhu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets
Alexandre E. Nowill, Manuel Caruso, Pedro O. de Campos‐Lima
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV
Lorie Marchitto, Debashree Chatterjee, Shilei Ding, et al.
Viruses (2023) Vol. 15, Iss. 10, pp. 2004-2004
Open Access | Times Cited: 5
COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2
Wei‐Chun Chen, Shu-Yu Hu, Ching‐Fen Shen, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1425-1425
Open Access | Times Cited: 3
Immunogenicity of Tetravalent Protein Vaccine, SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: a Phase 2 Trial
Jihai Tang, Qinghua Xu, C. Zhu, et al.
(2023)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top